来自中国的田中的Cyperus difformis种群中多种除草剂耐药性
Xianyan Chen1, Yonglin Ma2, Mengge Huang1
1Key Laboratory of Green Prevention and Control on Fruits and Vegetables in South China Ministry of Agriculture and Rural Affairs, Guangxi Key Laboratory of Biology for Crop Diseases and Insect Pests, Plant Protection Research Institute, Guangxi Academy of Agricultural Sciences, Nanning 530007, China; Institute of Pesticide and Environmental Toxicology, Guangxi University, Nanning 530004, China.
Pesticide biochemistry and physiology
|September 4, 2023
概括
在中国的田中,Cyperus difformis的除草剂耐药性是一个日益严重的问题. 一个群体 (GX-35) 进化了对除草剂的多重耐药性,这是由目标部位突变和增强的排毒机制驱动的.
科学领域:
- 农业学是一种农业学.
- 植物科学 植物科学
- 生物化学 生化学
背景情况:
- 抗除草药性Cyperus difformis (大米) 是大米种植的一个重大挑战,特别是在中国.
- 乙酸乳酸合成酶 (ALS) 抑制除草剂,辅酶除草剂和光合作用II (PSII) 抑制剂通常用于杂草控制.
研究的目的:
- 来自中国的Cyperus difformis (GX-35) 种群中进化的除草剂耐药性机制的研究.
- 评估对多种除草剂类别的耐药性水平,包括ALS抑制剂,辅素除草剂和PSII抑制剂.
主要方法:
- 测试了C. difformis群体GX-35对五种ALS抑制除草剂,MCPA (auxin) 和bentazone (PSII抑制剂) 的反应.
- 分析了ALS基因表达,并确定了ALS基因中的突变.
- 研究了细胞染色体P450 (CYP) 和ATP结合盒 (ABC) 载体基因以及UDP-glucuronosyltransferase (UGT) 基因的表达.
主要成果:
- 种群GX-35对多种ALS抑制除草剂 (13-1253倍) 和MCPA (21倍) 呈现出高耐药性,但不表现出本塔.
- 确定了ALS基因中的关键Asp376Glu突变,减少ALS除草剂抑制的酶.
- 观察到多个CYP,ABC载体和UGT基因的过度表达和/或诱导,这表明除草剂代谢和排毒增强.
结论:
- 在中国的田中,GX-35种群已经发展出多种除草剂耐药性.
- 耐药性归因于目标部位 (ALS突变) 和非目标部位 (通过基因表达增强新陈代谢) 的机制.
- 综合杂草管理策略对于控制抗除草剂耐药的Cyperus difformis至关重要.
相关概念视频
Responses to Drought and Flooding
10.7K
Water plays a significant role in the life cycle of plants. However, insufficient or excess of water can be detrimental and pose a serious threat to plants.
10.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


